{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T03:24:33Z","timestamp":1786937073487,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100031022","name":"Center for Cancer Research","doi-asserted-by":"publisher","award":["R01-CA290014"],"award-info":[{"award-number":["R01-CA290014"]}],"id":[{"id":"10.13039\/100031022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Elevated levels of carcinoembryonic antigen (CEA) are strongly associated with several malignancies, including colorectal and hepatic adenocarcinomas, making CEA a clinically valuable biomarker. Targeted molecular imaging using positron emission tomography (PET) in combination with CEA-specific tracers offers the potential for improved tumor detection and longitudinal disease monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We developed a nanoemulsion (NE) platform incorporating a fluorous-encapsulated radiometal (FERM) chelate, in which\n                      <jats:sup>89<\/jats:sup>\n                      Zr is complexed to a fluorinated hydroxamic acid chelator sequestered within the fluorous core of (~200\u00a0nm) NE droplets. CEA targeting was achieved using a humanized anti-CEA antibody functionalized with an azide group and conjugated via copper-free click chemistry to \u201cclick-ready\u201d NEs bearing dibenzocyclooctyne (DBCO) moieties within the surfactant layer.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In vitro studies demonstrated specific binding of the targeted NEs in both protein- and cell-based assays using LS174T cells. In vivo PET\/CT imaging of LS174T xenografts in nude mice revealed selective accumulation of the antibody-functionalized\n                      <jats:sup>89<\/jats:sup>\n                      Zr-labeled NE in tumors within 4\u2013120\u00a0h post injection, with target specificity validated by immunohistopathology. Clearance occurred predominantly through the spleen and liver, consistent with reticuloendothelial system uptake.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Click-ready FERM NEs form a stable colloidal suspension of nanoscale droplets with a high radiometal payload and PET sensitivity. This targeted imaging platform shows strong potential for early detection and monitoring of cancer-associated biomarkers such as CEA. The modular design enables facile adaptation to a wide range of targeting ligands, supporting applications in molecular imaging and therapeutic delivery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12951-026-04639-0","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T06:46:41Z","timestamp":1781074001000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted 89Zr-Labeled metallofluorocarbon nanoemulsion for carcinoembryonic antigen PET"],"prefix":"10.1186","volume":"24","author":[{"given":"Keith","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyu","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Varner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Messer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric T.","family":"Ahrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"issue":"2","key":"4639_CR1","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/0092-8674(89)90970-7","volume":"57","author":"S Benchimol","year":"1989","unstructured":"Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners CP. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell. 1989;57(2):327\u201334.","journal-title":"Cell"},{"issue":"3","key":"4639_CR2","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1084\/jem.122.3.467","volume":"122","author":"P Gold","year":"1965","unstructured":"Gold P, Freedman SO. Specific carcinoembryonic antigens of the human digestive system. J Exp Med. 1965;122(3):467\u201381.","journal-title":"J Exp Med"},{"issue":"4","key":"4639_CR3","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S1040-8428(85)80008-1","volume":"2","author":"JE Shively","year":"1985","unstructured":"Shively JE, Beatty JD. CEA-related antigens: Molecular biology and clinical significance. Crit Rev Oncol Hematol. 1985;2(4):355\u201399.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3\u20134","key":"4639_CR4","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s10555-013-9444-6","volume":"32","author":"N Beauchemin","year":"2013","unstructured":"Beauchemin N, Arabzadeh A. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer Metastasis Rev. 2013;32(3\u20134):643\u201371.","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"4639_CR5","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/bjc.2012.605","volume":"108","author":"JP Tiernan","year":"2013","unstructured":"Tiernan JP, Perry SL, Verghese ET, West NP, Yeluri S, Jayne DG, et al. Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting. Br J Cancer. 2013;108(3):662\u20137.","journal-title":"Br J Cancer"},{"issue":"3","key":"4639_CR6","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"4639_CR7","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1101\/gad.1047403","volume":"17","author":"TF Massoud","year":"2003","unstructured":"Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 2003;17(5):545\u201380.","journal-title":"Genes Dev"},{"issue":"12","key":"4639_CR8","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.2174\/156802610791384225","volume":"10","author":"K Chen","year":"2010","unstructured":"Chen K, Chen X. Design and development of molecular imaging probes. Curr Top Med Chem. 2010;10(12):1227\u201336.","journal-title":"Curr Top Med Chem"},{"issue":"8","key":"4639_CR9","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1021\/acs.chemrev.9b00738","volume":"120","author":"W Wei","year":"2020","unstructured":"Wei W, Rosenkrans ZT, Liu J, Huang G, Luo QY, Cai W. ImmunoPET: concept, design, and applications. Chem Rev. 2020;120(8):3787\u2013851.","journal-title":"Chem Rev"},{"issue":"14","key":"4639_CR10","doi-asserted-by":"publisher","first-page":"5333","DOI":"10.1021\/jm100623e","volume":"53","author":"SR Banerjee","year":"2010","unstructured":"Banerjee SR, Pullambhatla M, Byun Y, Nimmagadda S, Green G, Fox JJ, Horti A, Mease RC, Pomper MG. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem. 2010;53(14):5333\u201341.","journal-title":"J Med Chem"},{"issue":"6","key":"4639_CR11","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","volume":"70","author":"M Perera","year":"2016","unstructured":"Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, et al. Sensitivity, specificity, and predictors of positive 68Ga\u2013prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: A systematic review and meta-analysis. Eur Urol. 2016;70(6):926\u201337.","journal-title":"Eur Urol"},{"issue":"9","key":"4639_CR12","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1021\/cbmi.4c00030","volume":"2","author":"M Shabsigh","year":"2024","unstructured":"Shabsigh M, Solomon LA. Peptide PET imaging: A review of recent developments and a look at the future of radiometal-labeled peptides in medicine. Chemical & Biomedical Imaging. 2024;2(9):615\u201330.","journal-title":"Chemical & Biomedical Imaging"},{"issue":"8","key":"4639_CR13","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.2967\/jnumed.108.051243","volume":"49","author":"HY Lee","year":"2008","unstructured":"Lee HY, Li Z, Chen K, Hsu AR, Xu C, Xie J, et al. PET\/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J Nucl Med. 2008;49(8):1371\u20139.","journal-title":"J Nucl Med"},{"issue":"1","key":"4639_CR14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.7150\/thno.13242","volume":"6","author":"H Chen","year":"2016","unstructured":"Chen H, Niu G, Wu H, Chen X. Clinical Application of Radiolabeled RGD Peptides for PET Imaging of Integrin \u03b1v\u03b23. Theranostics. 2016;6(1):78\u201392.","journal-title":"Theranostics"},{"issue":"7","key":"4639_CR15","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.2967\/jnumed.107.039859","volume":"48","author":"ZB Li","year":"2007","unstructured":"Li ZB, Cai W, Cao Q, Chen K, Wu Z, He L, et al. 64Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor \u03b1v\u03b23 integrin expression. J Nucl Med. 2007;48(7):1162\u201371.","journal-title":"J Nucl Med"},{"issue":"12","key":"4639_CR16","first-page":"1962","volume":"44","author":"G Sundaresan","year":"2003","unstructured":"Sundaresan G, Yazaki PJ, Shively JE, Finn RD, Larson SM, Raubitschek AA, et al. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med. 2003;44(12):1962\u20139.","journal-title":"J Nucl Med"},{"issue":"12","key":"4639_CR17","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1007\/s00259-023-06313-1","volume":"50","author":"L Li","year":"2023","unstructured":"Li L, Lin X, Wang L, Ma X, Zeng Z, Liu F, Jia B, Zhu H, Wu A, Yang Z. Immuno-PET of colorectal cancer with a CEA-targeted [68 Ga]Ga-nanobody: from bench to bedside. Eur J Nucl Med Mol Imaging. 2023;50(12):3735\u201349.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 3","key":"4639_CR18","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.2967\/jnumed.121.262751","volume":"62","author":"RL Wahl","year":"2021","unstructured":"Wahl RL, Sgouros G, Iravani A, Jacene H, Pryma D, Saboury B, Capala J, Graves SA. Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns. J Nucl Med. 2021;62(Suppl 3):S23\u201335.","journal-title":"J Nucl Med"},{"issue":"7","key":"4639_CR19","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1021\/acs.bioconjchem.1c00136","volume":"32","author":"M Chomet","year":"2021","unstructured":"Chomet M, van Dongen G, Vugts DJ. State of the art in radiolabeling of antibodies with common and uncommon radiometals for preclinical and clinical Immuno-PET. Bioconjug Chem. 2021;32(7):1315\u201330.","journal-title":"Bioconjug Chem"},{"issue":"4","key":"4639_CR20","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.molmed.2020.12.006","volume":"27","author":"VI B\u00f6hmer","year":"2021","unstructured":"B\u00f6hmer VI, Szymanski W, Feringa BL, Elsinga PH. Multivalent probes in molecular imaging: reality or future? Trends Mol Med. 2021;27(4):379\u201393.","journal-title":"Trends Mol Med"},{"issue":"11","key":"4639_CR21","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1021\/mp500306k","volume":"11","author":"F Chen","year":"2014","unstructured":"Chen F, Nayak TR, Goel S, Valdovinos HF, Hong H, Theuer CP, et al. In vivo tumor vasculature targeted PET\/NIRF imaging with TRC105(Fab)-conjugated, dual-labeled mesoporous silica nanoparticles. Mol Pharm. 2014;11(11):4007\u201314.","journal-title":"Mol Pharm"},{"issue":"11","key":"4639_CR22","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.2967\/jnumed.109.061846","volume":"50","author":"MJ Welch","year":"2009","unstructured":"Welch MJ, Hawker CJ, Wooley KL. The advantages of nanoparticles for PET. J Nucl Med. 2009;50(11):1743\u20136.","journal-title":"J Nucl Med"},{"issue":"21","key":"4639_CR23","doi-asserted-by":"publisher","first-page":"5406","DOI":"10.1016\/j.biomaterials.2012.04.036","volume":"33","author":"EA Simone","year":"2012","unstructured":"Simone EA, Zern BJ, Chacko AM, Mikitsh JL, Blankemeyer ER, Muro S, et al. Endothelial targeting of polymeric nanoparticles stably labeled with the PET imaging radioisotope iodine-124. Biomaterials. 2012;33(21):5406\u201313.","journal-title":"Biomaterials"},{"issue":"6","key":"4639_CR24","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1002\/mrm.25454","volume":"72","author":"ET Ahrens","year":"2014","unstructured":"Ahrens ET, Helfer BM, O\u2019Hanlon CF, Schirda C. Clinical cell therapy imaging using a perfluorocarbon tracer and fluorine-19 MRI. Magn Reson Med. 2014;72(6):1696\u2013701.","journal-title":"Magn Reson Med"},{"issue":"8","key":"4639_CR25","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.2967\/jnumed.120.255273","volume":"62","author":"C Wang","year":"2021","unstructured":"Wang C, Leach BI, Lister D, Adams SR, Xu H, Hoh C, et al. Metallofluorocarbon nanoemulsion for inflammatory macrophage detection via PET and MRI. J Nucl Med. 2021;62(8):1146\u201353.","journal-title":"J Nucl Med"},{"issue":"14","key":"4639_CR26","doi-asserted-by":"publisher","first-page":"4251","DOI":"10.1002\/pola.21508","volume":"44","author":"MP Krafft","year":"2006","unstructured":"Krafft MP. Highly fluorinated compounds induce phase separation in, and nanostructuration of liquid media. Possible impact on, and use in chemical reactivity control. J Polym Sci Part Polym Chem. 2006;44(14):4251\u20138.","journal-title":"J Polym Sci Part Polym Chem"},{"issue":"2","key":"4639_CR27","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1021\/acsnanoscienceau.1c00016","volume":"2","author":"AS Perez","year":"2022","unstructured":"Perez AS, Zhou J, Leach B, Xu H, Lister D, Adams SR, et al. Click-ready perfluorocarbon nanoemulsion for 19F MRI and multimodal cellular detection. ACS Nanosci Au. 2022;2(2):102\u201310.","journal-title":"ACS Nanosci Au"},{"issue":"8","key":"4639_CR28","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/j.1525-1594.2009.00944.x","volume":"34","author":"CI Castro","year":"2010","unstructured":"Castro CI, Briceno JC. Perfluorocarbon-based oxygen carriers: review of products and trials. Artif Organs. 2010;34(8):622\u201334.","journal-title":"Artif Organs"},{"key":"4639_CR29","unstructured":"Johnson I, Spence M. Fluorophores and Their Amine-Reactive Derivatives. In: The Molecular Probes handbook. A guide to fluorescent probes and labeling technologies. 11th ed. Invitrogen; 2010. p. 11\u201396."},{"issue":"9","key":"4639_CR30","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1021\/ja077388j","volume":"130","author":"JM Janjic","year":"2008","unstructured":"Janjic JM, Srinivas M, Kadayakkara DKK, Ahrens ET. Self-delivering nanoemulsions for dual fluorine-19 MRI and fluorescence detection. J Am Chem Soc. 2008;130(9):2832\u201341.","journal-title":"J Am Chem Soc"},{"issue":"28","key":"4639_CR31","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.1002\/adma.201200653","volume":"24","author":"MJ Sailor","year":"2012","unstructured":"Sailor MJ, Park JH. Hybrid nanoparticles for detection and treatment of cancer. Adv Mater. 2012;24(28):3779\u2013802.","journal-title":"Adv Mater"},{"issue":"1","key":"4639_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1081\/BIO-200046659","volume":"33","author":"JG Riess","year":"2005","unstructured":"Riess JG. Understanding the fundamentals of perfluorocarbons and perfluorocarbon emulsions relevant to in vivo oxygen delivery. Artif Cells Blood Substit Immobil Biotechnol. 2005;33(1):47\u201363.","journal-title":"Artif Cells Blood Substit Immobil Biotechnol"},{"issue":"7","key":"4639_CR33","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.7150\/thno.103820","volume":"15","author":"R Vichare","year":"2025","unstructured":"Vichare R, Janjic J. Perfluorocarbon nanoemulsions in drug delivery: design, development, and manufacturing. Theranostics. 2025;15(7):3013\u201334.","journal-title":"Theranostics"},{"issue":"1","key":"4639_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/ajh.2830160103","volume":"16","author":"O Castro","year":"1984","unstructured":"Castro O, Nesbitt AE, Lyles D. Effect of a perfluorocarbon emulsion (Fluosol-DA) on reticuloendothelial system clearance function. Am J Hematol. 1984;16(1):15\u201321.","journal-title":"Am J Hematol"},{"issue":"8","key":"4639_CR35","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/nbt1121","volume":"23","author":"ET Ahrens","year":"2005","unstructured":"Ahrens ET, Flores R, Xu H, Morel PA. In vivo imaging platform for tracking immunotherapeutic cells. Nat Biotechnol. 2005;23(8):983\u20137.","journal-title":"Nat Biotechnol"},{"issue":"49","key":"4639_CR36","doi-asserted-by":"publisher","first-page":"18445","DOI":"10.1021\/ja407573m","volume":"135","author":"MJ Patrick","year":"2013","unstructured":"Patrick MJ, Janjic JM, Teng H, O\u2019Hear MR, Brown CW, Stokum JA, Schmidt BF, Ahrens ET, Waggoner AS. Intracellular pH measurements using perfluorocarbon nanoemulsions. J Am Chem Soc. 2013;135(49):18445\u201357.","journal-title":"J Am Chem Soc"},{"issue":"6","key":"4639_CR37","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/nmat4585","volume":"15","author":"AA Kislukhin","year":"2016","unstructured":"Kislukhin AA, Xu H, Adams SR, Narsinh KH, Tsien RY, Ahrens ET. Paramagnetic fluorinated nanoemulsions for sensitive cellular fluorine-19 magnetic resonance imaging. Nat Mater. 2016;15(6):662.","journal-title":"Nat Mater"},{"issue":"9","key":"4639_CR38","doi-asserted-by":"publisher","first-page":"3836","DOI":"10.1021\/acsabm.9b00455","volume":"2","author":"C Wang","year":"2019","unstructured":"Wang C, Adams SR, Xu H, Zhu W, Ahrens ET. \u03b2-Diketonate-Iron(III) Complex: A Versatile Fluorine-19 MRI Signal Enhancement Agent. ACS Appl Bio Mater. 2019;2(9):3836\u201342.","journal-title":"ACS Appl Bio Mater"},{"issue":"1","key":"4639_CR39","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1021\/acsnano.8b04881","volume":"13","author":"AH Jahromi","year":"2019","unstructured":"Jahromi AH, Wang C, Adams SR, Zhu W, Narsinh K, Xu H, Gray DL, Tsien RY, Ahrens ET. Fluorous-Soluble Metal Chelate for Sensitive Fluorine-19 Magnetic Resonance Imaging Nanoemulsion Probes. ACS Nano. 2019;13(1):143\u201351.","journal-title":"ACS Nano"},{"issue":"19","key":"4639_CR40","doi-asserted-by":"publisher","first-page":"17181","DOI":"10.1021\/acsomega.3c01547","volume":"8","author":"B Radaram","year":"2023","unstructured":"Radaram B, Glazer SE, Yang P, Li C-W, Hung M-C, Gammon ST, et al. Evaluation of 89Zr-labeled Anti-PD-L1 monoclonal antibodies using DFO and novel HOPO analogues as chelating agents for Immuno-PET. ACS Omega. 2023;8(19):17181\u201394.","journal-title":"ACS Omega"},{"issue":"12","key":"4639_CR41","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1007\/s00259-023-06313-1","volume":"50","author":"L Li","year":"2023","unstructured":"Li L, Lin X, Wang L, Ma X, Zeng Z, Liu F, Jia B, Zhu H, Wu A, Yang Z. Immuno-PET of colorectal cancer with a CEA-targeted [68 Ga]Ga-nanobody: from bench to bedside. Eur J Nucl Med Mol Imaging. 2023;50(12):3735\u20134941.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"4639_CR42","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1186\/s12951-025-03868-z","volume":"23","author":"L Zhang","year":"2025","unstructured":"Zhang L, Zhou M, Lu C, Zhao P, Shi N, Zhou Y, Yao C, Yang X, Tian J, Wang J, Ma Y, Huang Q, Xu C, Gao P, Zhou W, Hu S, Luo L. A high-affinity CEA-targeted nanobody for 68Ga PET imaging and 177Lu-based radioisotope therapy: preclinical and first-in-human evaluation. J Nanobiotechnol. 2025;23(1):734.","journal-title":"J Nanobiotechnol"},{"issue":"15","key":"4639_CR43","doi-asserted-by":"publisher","first-page":"8495","DOI":"10.1073\/pnas.150228297","volume":"97","author":"AM Wu","year":"2000","unstructured":"Wu AM, Yazaki PJ, Tsai S, Nguyen K, Anderson AL, McCarthy DW, et al. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc Natl Acad Sci U S A. 2000;97(15):8495\u2013500.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"4639_CR44","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1021\/bc700161p","volume":"19","author":"L Li","year":"2008","unstructured":"Li L, Bading J, Yazaki PJ, Ahuja AH, Crow D, Colcher D, Williams LE, Wong JY, Raubitschek A, Shively JE. A versatile bifunctional chelate for radiolabeling humanized anti-CEA antibody with In-111 and Cu-64 at either thiol or amino groups: PET imaging of CEA-positive tumors with whole antibodies. Bioconjug Chem. 2008;19(1):89\u201396.","journal-title":"Bioconjug Chem"},{"issue":"7","key":"4639_CR45","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.2967\/jnumed.123.267107","volume":"65","author":"C Imberti","year":"2024","unstructured":"Imberti C, De Gregorio R, Korsen JA, Hoang TT, Khitrov S, Kalidindi T, Nandakumar S, Park J, Zaidi S, Pillarsetty NVK, Lewis JS. CEACAM5-Targeted Immuno-PET in Androgen Receptor-Negative Prostate Cancer. J Nucl Med. 2024;65(7):1043\u201350.","journal-title":"J Nucl Med"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-04639-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04639-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04639-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T02:49:00Z","timestamp":1786934940000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-026-04639-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4639"],"URL":"https:\/\/doi.org\/10.1186\/s12951-026-04639-0","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"3 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments followed protocols approved by the University of California San Diego\u2019s Institutional Animal Care and Use Committee.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"E.T.A. is a founder, shareholder and board member of Cali Biomedical Inc. The other authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"766"}}